Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.

Episode 315

0:00-56:27

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in dementia with Lewy bodies (DLB) and commercial planning for an anticipated launch. Winton talks about CMC and manufacturing scale-up, partnership, communicating with regulators and the benefits of global regulatory alignment on protocols for the Phase 3 trial. He also talks about building value through HEOR and payer engagement in parallel with clinical development, and pricing in the context of policy changes and shifting global launch dynamics. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Publisher

Business Of Biotech

Published

July 20, 2026

Duration

56 min

Format

Podcast

Category

Issues · Business

Source

RSS feed

Host

Ben Comer

BO

Business Of Biotech

@businessofbiotech

#stagedevelopment #commercialplanning #cervomedsmattwinton #management #lifesciences

The Nile